What is the appropriate dosing regimen for injectable testosterone in women to achieve physiological serum testosterone levels?

Injectable Testosterone Dosing for Women

For women requiring testosterone therapy, use approximately one-tenth of the male dose: start with 10-25 mg of testosterone cypionate or enanthate intramuscularly or subcutaneously every 1-2 weeks, titrating to maintain serum testosterone levels in the physiologic premenopausal range (30-100 ng/dL).

Critical Context: Off-Label Use and Regulatory Gap

All injectable testosterone use in women is off-label, as no female-specific testosterone formulation is FDA-approved in most countries. The available evidence comes from guidelines addressing female sexual dysfunction and transgender medicine, along with FDA labeling for male formulations 1, 2, 3.

Dosing Strategy

Starting Dose

• Begin with 10-25 mg testosterone cypionate or enanthate every 1-2 weeks 4, 5, 6
• This represents approximately 1/10th the typical male dose (which ranges from 50-200 mg every 2-4 weeks) 3
• For transgender female-to-male patients (who require masculinization), doses of 50-150 mg weekly are used, but this produces supraphysiologic levels inappropriate for cisgender women 4

Route of Administration

Both intramuscular (IM) and subcutaneous (SC) routes are effective:

• Subcutaneous injection is equally effective and better tolerated than IM administration 4
• SC injections can be self-administered in the thigh or abdomen
• IM injections require gluteal administration 3

Target Testosterone Levels

Aim for serum total testosterone in the physiologic premenopausal range: 30-100 ng/dL 1, 5, 6

This is critical because:

• Supraphysiologic levels (>100 ng/dL) increase risk of virilization and adverse effects
• Injectable formulations and pellets frequently produce excessive levels and are explicitly not recommended by consensus guidelines 1

Monitoring Protocol

Baseline Assessment

• Measure total testosterone before initiating therapy 1, 2, 5
• Document symptoms (particularly if treating hypoactive sexual desire disorder)
• Screen for contraindications: active breast cancer, cardiovascular disease, untreated polycythemia

Follow-Up Monitoring

1. At 3-6 weeks after initiation:

   • Measure serum total testosterone midway between injections 7, 1, 5
   • Adjust dose if levels are outside target range
   • Assess for signs of androgen excess (acne, hirsutism, voice changes, clitoromegaly)

2. Every 6 months during ongoing therapy:

   • Monitor testosterone levels to screen for overuse 1, 2, 5
   • Assess clinical response and adverse effects
   • Check hematocrit (stop if >54%) 7

3. At 6 months:

   • Discontinue therapy if no clinical benefit 1

Dose Adjustments

If testosterone levels are:

• <30 ng/dL: Increase dose by 5-10 mg per injection
• >100 ng/dL: Decrease dose by 5-10 mg per injection or extend dosing interval
• 30-100 ng/dL with inadequate symptom relief: Consider increasing dose cautiously while monitoring for virilization

The significant inter-individual variability in testosterone metabolism (coefficient of variation 35-43%) means dosing must be individualized based on serum levels, not just body weight 8.

Critical Safety Considerations

Contraindications to Injectable Testosterone

• Avoid testosterone pellets and standard male injection doses - these consistently produce supraphysiologic levels 1, 8
• Baseline hematocrit >50% is a relative contraindication 7
• Active breast cancer or cardiovascular disease

Common Pitfalls

1. Using male dosing regimens: The standard male dose of 100-200 mg every 2 weeks produces testosterone levels 5-10 times higher than appropriate for women 3

2. Relying on compounded preparations: These lack quality control and standardized dosing; use FDA-approved male formulations at reduced doses instead 1, 2, 5

3. Measuring testosterone at wrong time: Always measure midway between injections to avoid falsely elevated peak levels 7

4. Ignoring clinical signs of excess: Acne, hirsutism, voice deepening, and clitoromegaly indicate excessive dosing regardless of serum levels 1, 5

Evidence Quality and Limitations

The strongest evidence comes from the 2019 Global Consensus Position Statement 1 and 2021 International Society for the Study of Women's Sexual Health guidelines 5, 6, which represent expert consensus based on limited randomized trial data. The Endocrine Society guidelines 2 recommend against routine testosterone use in women except for specific indications like HSDD in postmenopausal women.

Key limitation: Most safety and efficacy data come from transdermal preparations, not injectables. Injectable testosterone data in cisgender women is extrapolated from transgender medicine 4 and requires careful dose reduction to achieve physiologic rather than masculinizing levels.

The lack of FDA-approved female formulations forces clinicians to use male preparations off-label, making precise dosing challenging and emphasizing the critical importance of therapeutic drug monitoring 1, 5.